When was Boston Biomedical founded?

Boston Biomedical was founded in 2006 and raised its 1st funding round 4 years after it was founded.

Where is Boston Biomedical located?

Boston Biomedical is headquartered in Boston, United States.

How many employees does Boston Biomedical have?

As of Mar 01, 2026, the latest employee count at Boston Biomedical is 10 - 49.

Is Boston Biomedical a funded company?

Boston Biomedical is a funded company, having raised a total of $2M across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 16, 2010.

When was the latest funding round of Boston Biomedical?

Boston Biomedical's latest funding was a $***** Seed round on Jun 15, 2010, with participation from 0 investor.

Where does Boston Biomedical rank among its competitors?

Boston Biomedical ranks 757th amongst 3261 active competitors, of which 1122 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Boston Biomedical?

Boston Biomedical's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

Boston Biomedical - 2026 Company Profile, Funding & Competitors

Company Details

Boston Biomedical is a privately held biotechnology company focusing on research and development of novel therapeutics to treat cancer. Beginning with initial focus on cancer stemcell pathways, company today has more than 20 clinical programs in pipeline. Two lead products at various phases of clinical trials for different types of cancer are Napabucasin and BB503. Other oncology programs include DSP-7888, an investigational agent approved by USFDA. Company got acquired by ds-pharma in 2012 for 200M USD upfront with milestone achievement being upto as high as 2.6B USD.

Website: www.bostonbiomedical.com/
Social

Key Metrics

Founded Year

2006

Location

Boston, United States

Stage

Acquired

Total Funding

$2M in 2 rounds

Latest Funding Round

Seed, Jun 15, 2010, $*****

Investors

Mitsui Global Investment & 1 more

Ranked

757^th among 3261 active competitors

Employee Count

10 - 49 as on Mar 01, 2026

Similar Companies

Jazz Pharmaceuticals & 2977 more

Exit Details

Acquired by Sumitomo Dainippon Pharma (Feb 29, 2012)

View Boston Biomedical's full profile

Boston Biomedical got acquired by Sumitomo Dainippon Pharma on Feb 29, 2012 at an acquisition amount of $*****.

Click here to take a look at Boston Biomedical's acquisition in detail

Boston Biomedical has raised a total funding of $2M over 2 rounds. Its first funding round was on Apr 16, 2010. Boston Biomedical has 2 institutional investors.

Here is the list of recent funding rounds of Boston Biomedical:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 15, 2010	1807036	Seed	8546789	9813866	6433261	9415972
Apr 16, 2010	8136455	Grant (prize money)	5094450	7680177	8404351	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Boston Biomedical's funding rounds and investors

Boston Biomedical's employee count trend

Boston Biomedical has 10 - 49 employees as of Mar 26. Here is Boston Biomedical's employee count trend over the years:

Employee count trend for Boston Biomedical

Uncover Boston Biomedical's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Boston Biomedical include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Boston Biomedical, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Eight Roads Ventures & 23 others	71/100
757th	Boston Biomedical 2006, Boston (United States), Acquired	Develops novel therapeutics for treatment of cancer	$2M	Mitsui Global Investment, HHS	43/100